Analysis of the Evaluated and Marketed Drugs in China from 2015 to 2023
Objective To understand the overall situation of evaluated and marketed drugs in China.Methods The relevant information on drugs evaluated and marketed by the Center for Drug Evaluation(CDE)of the National Medical Products Administration(NMPA)from 2015 to 2023 was searched,the development trend of drugs marketed in China from three aspects:number of marketed drugs,innovation level,and treatment field were analyzed,and reasonable suggestions for future drug research and development innovation in China were provided from policy and industry perspectives.Results In terms of the number of marketed drugs,1 138 drugs were evaluated and marketed in China from 2015 to 2023,including 168 Class 1 new drugs,315 improved new drugs,and 655 other types of new drugs,with an average increase of about 28.22％.The number of new drugs for traditional Chinese medicine(24)was fewer than that for chemical drugs(680)and biological products(434).In terms of innovation levels,the proportions of chemical drugs in Class 1,improved,and other types of new drugs were 60.71％,39.05％,and 69.47％,respectively;the proportions of biological products were 30.95％,58.73％,and 30.08％,respectively;the proportions of traditional Chinese medicine were 8.33％,2.22％,and 0.46％,respectively;the proportions of Class 1 new drugs for traditional Chinese medicine,chemical drugs,and biological products in their own kinds of drugs were 58.33％,15.00％,and 11.98％,respectively.In terms of the treatment field,the number of anti-tumor drugs(391,accounting for 34.36％)was the highest,and the homogenization competition was obvious.Conclusion It is recommended that the national drug administration departments should pay more attention to the varieties of traditional Chinese medicine,increase the support of drug innovation policies,and constantly improve the research and development ability of new drugs and original new drugs of traditional Chinese medicine.Pharmaceutical manufacturers should focus on the original basic research,and improve the supply capacity and the development ability of new drugs.
evaluated and marketed drugpharmaceutical innovationnew drug research and developmentpharmaceutical industry
万方数据
维普
